Spero Therapeutics (NASDAQ:SPRO) Upgraded to “Hold” at Wall Street Zen

Spero Therapeutics (NASDAQ:SPRO) was upgraded by Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday.

Spero Therapeutics Trading Up 2.7%

Shares of SPRO stock opened at $3.02 on Friday. The business’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $1.05. The company has a market cap of $168.85 million, a PE ratio of -2.36 and a beta of 1.31. Spero Therapeutics has a 12-month low of $0.51 and a 12-month high of $3.06.

Spero Therapeutics (NASDAQ:SPRO) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.30. The business had revenue of $5.87 million for the quarter, compared to the consensus estimate of $11.00 million. Spero Therapeutics had a negative return on equity of 123.50% and a negative net margin of 156.48%. On average, equities analysts forecast that Spero Therapeutics will post -1.2 earnings per share for the current year.

Hedge Funds Weigh In On Spero Therapeutics

A number of large investors have recently made changes to their positions in SPRO. Monimus Capital Management LP acquired a new position in shares of Spero Therapeutics during the fourth quarter worth $320,000. Virtu Financial LLC purchased a new stake in shares of Spero Therapeutics during the fourth quarter valued at $47,000. Prudential Financial Inc. purchased a new stake in shares of Spero Therapeutics during the fourth quarter valued at $51,000. JPMorgan Chase & Co. grew its holdings in shares of Spero Therapeutics by 26,011.9% during the fourth quarter. JPMorgan Chase & Co. now owns 61,624 shares of the company’s stock valued at $63,000 after buying an additional 61,388 shares during the last quarter. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Spero Therapeutics by 7.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 801,277 shares of the company’s stock valued at $825,000 after buying an additional 57,818 shares during the last quarter. 25.60% of the stock is owned by institutional investors and hedge funds.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.